(Q43860199)

English

Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression.

scientific article published on 24 February 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Shahin Akhondzadeh

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Roya Abolfazli

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Mahdi Hosseini

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Ahmad Ghanizadeh

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Mina Tabrizi

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Maedeh Raznahan

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Mousa Golalizadeh

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

24 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Depression and Anxiety

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

28

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

297-302

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Major depression: emerging therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

Approved and investigational uses of modafinil : an evidence-based review

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

Do individuals with former amphetamine dependence have cognitive deficits?

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

A Systematic Review of Modafinil

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

The Future of Psychopharmacology of Depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

A prospective trial of modafinil as an adjunctive treatment of major depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

A retrospective chart review of the effects of modafinil on depression as monotherapy and as adjunctive therapy

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

Clinical pharmacokinetic profile of modafinil

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

21 January 2018

The future of depression psychopharmacology

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

7 January 2021

based on heuristic

inferred from DOI database lookup

Treating depression to full remission.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacology of antidepressants--characteristics of the ideal drug

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

7 January 2021

based on heuristic

inferred from DOI database lookup

Modafinil augmentation of antidepressant treatment in depression.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

7 January 2021

based on heuristic

inferred from DOI database lookup

Modafinil augmentation in depressed patients with partial response to antidepressants: a pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptom Checklist (SCL-92)

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20801

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DA.20801

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456039%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43860199&oldid=2189028378"